Business Standard

Monday, December 23, 2024 | 02:42 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Laurus Labs launches generic Lyrica in US to treat neuropathic conditions

Market size in the US for the API was about $5,497 million in FY19; firm says generic launch is one of its largest this year

The share of the top 10 Indian companies in the US generics market nearly doubled from 10.5 per cent in 2012-13 to 19.5 per cent in 2017-18
Premium

Representative Image

BS Reporter Hyderabad
Hyderbad-based Laurus Labs Ltd along with its exclusive distribution partner Rising Pharmaceuticals today announced the launch of generic version of Lyrica (pregabalin) capsules in the US market. 

Pregabalin capsules had approximately $5,497 million US sales in FY19, the company said quoting the  intercontinental marketing statistics (IMS) Health data. The drug is indicated for management of neuropathic pain caused by different health conditions.

"We are happy to develop and manufacture the Pregabalin capsules for our distribution partner Rising Pharmaceuticals in US. As we move forward in the finished dosage form (FDF) segment backed by our strong active pharmaceutical ingredient (API) manufacturing facilities, we
Topics : Laurus Labs

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in